Building on the positive phase II results reported in June 2018 for pamrevlumab to treat pancreatic cancer, the first dose has been administered in Fibrogen Inc.'s phase III study in patients with unresectable locally advanced pancreatic cancer.
Eli Lilly and Co.'s $1.48 billion acquisition of Armo Biosciences Inc., intended to broadly bolster its immuno-oncology program, fell short of that goal in its first big test, a phase III trial in second-line pancreatic cancer called Sequoia.
Boston Biomedical Inc. shuttered phase III study Canstem111P of napabucasin for patients with metastatic pancreatic ductal adenocarcinoma, adding to the list of studies that have fallen in pancreatic cancer.
